Insulin aspart (AT278) vs Insulin aspart (Fiasp)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline

Insulin aspart (AT278)

Developed by Arecor Limited

Phase 1 in Type 2 Diabetespeptide
Partial signal

NCT05754424 · Phase 1 · completed

Every participant received AT278 and the active comparator insulin in random order, with neither participants nor staff knowing which was given at each visit, which is a solid design. But the trial measured a pharmacology lab readout rather than a real-world blood sugar or complication outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Area under the glucose infusion rate-time curve of insulin aspart (0 to 60 minutes): Glucose clamp trial in overweight/obese people with Type 2 Diabetes (NCT05754424, AT278 U500 vs NovoRapid U100 vs Humulin R U500, 41 participants per EASD 2024 data matching registry enrollment): primary non-inferiority endpoint met with statistical superiority -- 1.7-fold higher glucose-lowering effect in first 60 min (95% CI 1.32-2.96, p<0.0001). (met)

Result source: NCT05754424

Insulin aspart (Fiasp)

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2028 · NCT07652528 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointInsulin aspart (AT278)Insulin aspart (Fiasp)
HbA1c, change—Not reported6.6% vs 6.6%vs NovoRapidwk 26 · n 345NCT01819129
2 other results
  • -0.1% vs -0.1% wk 16 · n 544 · Phase 3 · primary NCT03268005
  • 6.8% vs 7.7% wk 18 · n 116 · Phase 3 · primary NCT01850615
Body weight, change (kg)—Not reported1.2 vs 1.1vs NovoRapidwk 16 · n 522NCT03268005
HbA1c below 7%—Not reported—Not reported
Fasting plasma glucose, change—Not reported0.6 vs 0.7vs NovoRapidwk 16 · n 533NCT03268005
3-point MACE (% with event)—Not reported—Not reported

HbA1c, change

Insulin aspart (AT278)
—Not reported
Insulin aspart (Fiasp)
6.6% vs 6.6%vs NovoRapidwk 26 · n 345NCT01819129
2 other results
  • -0.1% vs -0.1% wk 16 · n 544 · Phase 3 · primary NCT03268005
  • 6.8% vs 7.7% wk 18 · n 116 · Phase 3 · primary NCT01850615

Body weight, change (kg)

Insulin aspart (AT278)
—Not reported
Insulin aspart (Fiasp)
1.2 vs 1.1vs NovoRapidwk 16 · n 522NCT03268005

HbA1c below 7%

Insulin aspart (AT278)
—Not reported
Insulin aspart (Fiasp)
—Not reported

Fasting plasma glucose, change

Insulin aspart (AT278)
—Not reported
Insulin aspart (Fiasp)
0.6 vs 0.7vs NovoRapidwk 16 · n 533NCT03268005

3-point MACE (% with event)

Insulin aspart (AT278)
—Not reported
Insulin aspart (Fiasp)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Insulin aspart (AT278)
Glucose clamp trial in overweight/obese people with Type 2 Diabetes (NCT05754424, AT278 U500 vs NovoRapid U100 vs Humulin R U500, 41 participants per EASD 2024 data matching registry enrollment): primary non-inferiority endpoint met with statistical superiority -- 1.7-fold higher glucose-lowering effect in first 60 min (95% CI 1.32-2.96, p<0.0001). NCT05754424 · Phase 1 · design grade: moderate · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Insulin aspart (AT278): 0 of 4 rows · Insulin aspart (Fiasp): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricInsulin aspart (Fiasp)
Dropout rate
12.8%a
NCT01819129 · Phase 3
show 2 more results
7.8%
NCT01850615 · Phase 3 · combination
2.7%
NCT03268005 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
0.3%a
NCT01819129 · Phase 3
show 2 more results
1.7%
NCT01850615 · Phase 3 · combination
—
NCT03268005 · Phase 3 · registry result, not featured evidence
Serious AEs
4.4%a
NCT01819129 · Phase 3
show 2 more results
5.2%
NCT01850615 · Phase 3 · combination
7%
NCT03268005 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
a
urinary tract infection 5.9%
nasopharyngitis 5%
upper respiratory tract infection 4.7%
NCT01819129 · Phase 3
show 2 more results
diarrhoea 1.7%
NCT01850615 · Phase 3 · combination
nasopharyngitis 5.9%
NCT03268005 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Insulin aspart (Fiasp)

HbA1c 6.63% (n=345) vs 6.59% (n=344) NovoRapid @ 26wk
absolute change · percentage points
NCT01819129 · Phase 3
show 2 more results
6.78% (n=116) vs 7.7% (n=120) Basal @ 18wk
NCT01850615 · Phase 3 · combination
-0.15% (n=544) vs -0.09% (n=539) NovoRapid @ 16wk
NCT03268005 · Phase 3 · registry result, not featured evidence
PPG Excursion 4.55 vs 4.9 NovoRapid mmol/L @ 26wk
absolute change · mmol/L
NCT01819129 · Phase 3
show 1 more result
-0.43 vs 0.08 NovoRapid mmol/L @ 16wk
NCT03268005 · Phase 3 · registry result, not featured evidence
Fasting Plasma Glucose 0.56 vs 0.68 NovoRapid mmol/L @ 16wk
absolute change · mmol/L
NCT03268005 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7% 49.6% (n=546) vs 51.7% (n=545) NovoRapid @ 16wk
event count · % of participants
NCT03268005 · Phase 3 · registry result, not featured evidence · converted to % from 271 Participants as posted
HbA1c Less Than 7 Without Severe Hypoglycemia 48.5% (n=546) vs 51% (n=545) NovoRapid @ 16wk
event count · % of participants
NCT03268005 · Phase 3 · registry result, not featured evidence · converted to % from 265 Participants as posted
SMBG Daily Average -0.56 vs -0.5 NovoRapid mmol/L @ 16wk
absolute change · mmol/L
NCT03268005 · Phase 3 · registry result, not featured evidence
SMPG-mean Post Prandial Increment -0.48 vs -0.23 NovoRapid mmol/L @ 16wk
absolute change · mmol/L
All meals
NCT03268005 · Phase 3 · registry result, not featured evidence
Postprandial Glucose Leq 7.8 34.1% (n=546) vs 35.2% (n=545) NovoRapid @ 16wk
event count · % of participants
NCT03268005 · Phase 3 · registry result, not featured evidence · converted to % from 186 Participants as posted
Postprandial Glucose Leq 7.8 mmol/L Without Severe Hypoglycemia 33.3% (n=546) vs 34.9% (n=545) NovoRapid @ 16wk
event count · % of participants
NCT03268005 · Phase 3 · registry result, not featured evidence · converted to % from 182 Participants as posted
Weight 1.19 vs 1.12 NovoRapid kg @ 16wk
absolute change · kg
NCT03268005 · Phase 3 · registry result, not featured evidence
BMI 0.43 vs 0.4 NovoRapid kg @ 16wk
absolute change · kg
NCT03268005 · Phase 3 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin aspart (AT278)'s landscape · Insulin aspart (Fiasp)'s landscape